Sanders Morris Harris’s Crinetics Pharmaceuticals CRNX Stock Holding History

Sanders Morris Harris’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,100	Closed	-$766K	–	114
2026 Q1	$766K	Buy	+21,100	New	+$942K	0.12%	142
2025 Q4	–	Sell	-21,100	Closed	-$879K	–	89
2025 Q3	$879K	Buy	+21,100	New	+$675K	0.12%	120
2025 Q2	–	Sell	-21,100	Closed	-$646K	–	192
2025 Q1	$646K	Hold	21,100	–	–	0.1%	133
2024 Q4	$1.08M	Buy	21,100 +2,500	+13%	+$140K	0.16%	95
2024 Q3	$950K	Hold	18,600	–	–	0.16%	97
2024 Q2	$833K	Hold	18,600	–	–	0.14%	104
2024 Q1	$871K	Hold	18,600	–	–	0.16%	101
2023 Q4	$663K	Hold	18,600	–	–	0.33%	88
2023 Q3	$512K	Hold	18,600	–	–	0.11%	148
2023 Q2	$336K	Buy	+18,600	New	+$371K	0.07%	183
2023 Q1	–	Sell	-18,600	Closed	-$340K	–	167
2022 Q4	$340K	Hold	18,600	–	–	0.13%	143
2022 Q3	$353K	Hold	18,600	–	–	0.09%	173
2022 Q2	$351K	Hold	18,600	–	–	0.08%	185
2022 Q1	$408K	Hold	18,600	–	–	0.08%	190
2021 Q4	$523K	Hold	18,600	–	–	0.09%	163
2021 Q3	$368K	Hold	18,600	–	–	0.07%	211
2021 Q2	$388K	Hold	18,600	–	–	0.08%	212
2021 Q1	$306K	Hold	18,600	–	–	0.06%	225
2020 Q4	$263K	Hold	18,600	–	–	0.06%	227
2020 Q3	$311K	Buy	+18,600	New	+$284K	0.08%	200

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sanders Morris Harris's CRNX Position: Q2 2026 in Review

Sanders Morris Harris sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 21,100 shares — an estimated $766K sold.

Sanders Morris Harris first reported a position in CRNX in Q3 2020 and held it in 20 quarters. The position peaked at $1.08M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Sanders Morris Harris reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Sanders Morris Harris sold 21,100 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $766K.
Sanders Morris Harris first reported a position in Crinetics Pharmaceuticals in Q3 2020 and held it in 20 quarters.
Sanders Morris Harris's Crinetics Pharmaceuticals position peaked at $1.08M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.